Novartis IndiaNSE:NOVARTIND +1.93%62 Days Payable is 95.57 as of Mar. 2026, which is 22% below its 10-year median of 122.87. GuruFocus rates NSE:NOVARTIND with a GF Score™ of 62/100 and a GF Value™ of ₹642.38 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 927 Drug Manufacturers companies, Novartis India ranks better than 51.02% on this metric.
The historical rank and industry rank for Novartis India's Days Payable or its related term are showing as below:
NSE:NOVARTIND'
s Days Payable Range Over the Past 10 Years
Min: 83.73 Med: 122.87 Max: 178.35
Current: 91.53
During the past 13 years, Novartis India's highest Days Payable was 178.35. The lowest was 83.73. And the median was 122.87.
NSE:NOVARTIND's Days Payable is ranked better than 51.02% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs NSE:NOVARTIND: 91.53
Novartis India's Days Payable
increased
from Mar. 2025 (95.27) to Mar. 2026 (95.57).
It may suggest that Novartis Indiadelayed paying its suppliers.
Novartis India Days Payable Related Terms
Novartis India Days Payable Historical Data
* Premium members only.
The historical data trend for Novartis India's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:NOVARTIND vs ZTS, UTHR: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Novartis India's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novartis India Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novartis India's Days Payable distribution charts can be found below:
* The bar in red indicates where Novartis India's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Novartis India's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novartis India (NSE:NOVARTIND) has a Days Payable of 95.57 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Novartis India and its competitors. This is 22% below median its historical median of 122.87. Over the past decade, Novartis India's Days Payable has ranged from 83.73 to 178.35. According to the industry distribution chart, Novartis India ranks #454 out of 927 companies in the Drug Manufacturers industry, placing it in the top 49%.
Is Novartis India's Days Payable too high?
Novartis India's current Days Payable of 95.57 is 22% below median its 10-year median of 122.87. Over the past 10 years, this metric has ranged from a low of 83.73 to a high of 178.35. The Drug Manufacturers industry median Days Payable is 90.38. Novartis India's value of 95.57 is 5.7% above this industry median. Based on the distribution chart, Novartis India ranks #454 out of 927 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Novartis India has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novartis India's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Novartis India ranks #454 out of 927 companies for Days Payable. This puts Novartis India in the upper half of its industry. The industry median Days Payable is 90.38. Novartis India's value of 95.57 is 5.7% above this benchmark. Historically, Novartis India's own Days Payable has ranged from 83.73 to 178.35 over the past decade. While the company's 10-year median is 122.87 vs. the industry median of 90.38, Novartis India has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novartis India's current Days Payable of 95.57 is 5.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Novartis India and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novartis India's current Days Payable is 95.57, which is 22% below median its own 10-year median of 122.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis India stock overvalued right now?
Based on GuruFocus' analysis, Novartis India (NSE:NOVARTIND) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹642.38, compared to a current price of ₹1,494.60 — trading 132.7% above its estimated fair value. The current Days Payable is 95.57, which is 22% below median its 10-year median of 122.87 and 5.7% above the Drug Manufacturers industry median of 90.38. Novartis India's overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Novartis India (NSE:NOVARTIND), the current Days Payable is 95.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novartis India (NSE:NOVARTIND) Overvalued in 2026?
Based on GuruFocus' analysis, Novartis India stock appears to be overvalued.
The current stock price of ₹1,494.60 is trading 132.7% above its estimated GF Value™ of ₹642.38.
GuruFocus considers Novartis India to be Significantly Overvalued.
Key valuation signals for NSE:NOVARTIND:
Days Payable: 95.57 (22% below median its 10-year median of 122.87)
GF Value™: ₹642.38 vs. price of ₹1,494.60 (132.7% above fair value)
Industry Position: 5.7% above the Drug Manufacturers median (#454 of 927)
No single metric tells the full story. See the NSE:NOVARTIND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novartis India Ltd is an Indian-based pharmaceutical company. The company is engaged in the trading of Drugs and Pharmaceuticals. It derives revenue from operations in India. The company operates in a single business segment, namely Pharmaceutical Business. Its Pharmaceutical business focuses on Bone and Pain, Transplantation Immunology, and Neurosciences.
62GF Score
Get the complete analysis for NSE:NOVARTIND
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NOVARTIND has been successfully added to your 
